Preprint
Review

This version is not peer-reviewed.

Mitochondrial Nutrients and Toxicants in Healthy Longevity—An Evidence Informed Framework for Environmental and Therapeutic Exposures and Contextual Orthomolecular Nutrition

Submitted:

10 November 2026

Posted:

11 November 2026

You are already at the latest version

Abstract
Mitochondria supply the energy needed for organ function, movement, and recovery from stress. Protecting their function is therefore relevant to healthy aging. Mitochondrial care should address both avoidable injury and the potential of targeted nutrient treatment. This narrative review examines environmental stressors, medications across 14 therapeutic groups, and selected nutrient interventions. Its central message is that preventing deficiency and optimizing function are different objectives. Higher doses improve outcomes in some cofactor-responsive disorders; a small study in adult-onset mitochondrial myopathy also reported improved muscle performance. These findings justify testing whether greater nutrient availability can overcome impaired transport, utilization, or increased metabolic demand in other patients. The I-OM functional-dose hypothesis proposes that selected metabolic constraints may respond to exposures above conventional replacement doses. Author-recorded ranges define research questions rather than validated mitochondrial prescriptions. Published intervention results, author-proposed ranges, and documented adverse exposures are distinguished; unresolved historical claims are segregated in the appendix. The highest dose reported is not necessarily the most effective dose or a safe ceiling. Vitamin D concentrations likewise require interpretation alongside calcium metabolism, renal function, and clinical outcomes. The proposed approach combines exposure reduction, essential nutrient adequacy, and individualized investigation of higher-dose nutrition, guided by measurable functional benefit and harm. This framework supports a more active research agenda for mitochondrial health and healthy longevity; it does not establish a universal supplement regimen or demonstrate extension of human lifespan.
Keywords: 
;  ;  ;  ;  ;  ;  ;  ;  ;  

1. Introduction

Mitochondria connect substrate oxidation to ATP production while participating in redox signaling, calcium regulation, and cellular stress responses. Their performance cannot be inferred from the availability of calories alone. Vitamins supply coenzyme precursors; minerals participate in catalysis and electron transport; amino acids support protein synthesis and endogenous antioxidant systems. Adequate fuel delivery can therefore coexist with inadequate capacity to process that fuel.

1.1. Mitochondrial Function in Health and Healthy Longevity

Mitochondrial function is fundamental to health because oxidative phosphorylation supplies energy for sustained organ activity, including muscle contraction, cardiac work, neuronal signaling, and tissue maintenance. Mitochondria also coordinate metabolic adaptation and cellular stress responses. Their relevance to longevity therefore extends beyond ATP concentration to the capacity to maintain function and recover from physiological challenges.
Mitochondrial dysfunction is recognized within the hallmarks-of-aging framework and interacts with disturbed nutrient sensing, impaired cellular maintenance, senescence, and inflammation [1]. Experimental causality is supported by mice with defective mitochondrial DNA polymerase proofreading, which accumulate mitochondrial DNA mutations and develop premature aging phenotypes and reduced lifespan [2]. This model establishes a contribution of mitochondrial genome integrity to mammalian aging; it does not imply that mitochondrial dysfunction is the sole cause of normal human aging.
Human evidence connects mitochondrial energetics to clinically meaningful aspects of healthspan. In the Study of Muscle, Mobility and Aging, lower muscle mitochondrial energetics was associated with greater frailty in older women and men [3]. Because these data are observational, they do not establish that raising mitochondrial respiration alone prevents frailty. Human exercise interventions nevertheless demonstrate that skeletal-muscle mitochondrial respiration remains modifiable [4].
Preserving mitochondrial competence is consequently a biologically grounded objective for healthy longevity, particularly maintenance of mobility, metabolic resilience, and independence. Healthspan refers to preserved health and function, whereas lifespan refers to survival duration. Neither a mitochondrial biomarker improvement nor a plausible nutrient mechanism establishes extension of human lifespan. This review therefore evaluates exposure reduction and nutrient support primarily against functional, biochemical, and safety outcomes in their studied populations.

1.2. Rationale for Integrating Nutrients and Toxicants

Clinical discussions often separate nutritional deficiency, environmental exposure, and adverse drug effects into different specialties. A mitochondrial perspective reconnects these domains. An antibiotic can interfere with mitochondrial translation; a medication can diminish vitamin availability; smoking can alter respiratory-chain activity; and a nutrient deficiency can limit oxidative metabolism. These mechanisms differ in evidence strength and clinical consequence and should not be collapsed into a single diagnosis of “mitochondrial toxicity.”
The central proposition is that healthy-longevity strategies should assess avoidable mitochondrial injury and context-dependent nutrient requirements together. Exposure reduction addresses causes that supplementation may leave intact; appropriate nutrient provision addresses metabolic constraints that exposure reduction alone may not resolve. This integration is the contribution of the present review. The individual mechanisms and interventions are drawn from established literature; their organization within the I-OM framework is an author-proposed synthesis, not a newly validated treatment protocol. Orthomolecular dosing is operationalized as matching a physiologically relevant molecule, dose, and route to a defined need and outcome.

2. Scope and Evidence Approach

This is a targeted narrative review, not a systematic review or meta-analysis. Web-accessible PubMed records, selected full-text articles, NIH Office of Dietary Supplements fact sheets, and official medication labeling were consulted during preparation on 10 November 2026. Searches combined mitochondrial function or toxicity with drugs, tobacco, pesticides, air pollution, vitamins, minerals, coenzyme Q10, and nutrient dosing. Searches were used to locate sentinel studies and safety guidance; no exhaustive database export, duplicate screening, formal risk-of-bias assessment, or pooled analysis was performed. Recent publications were eligible, but coverage through the search date is not claimed to be complete.
Sources were selected for a direct mitochondrial endpoint, a clinically relevant medication-related nutrient effect, a human nutrient intervention, or dose-specific safety information. Primary studies were favored for concrete effect estimates; reviews and official assessments supplied broader context. Mechanistic studies were retained to explain pathways, with their model and exposure context identified. Representative source-finding topics included mitochondrial medicine dosing, drug-induced mitochondrial toxicity, metformin and B12 deficiency, statin muscle effects, nutrient pharmacokinetics, and specific supplement trials. There was no registered protocol, exhaustive search of all databases, independent duplicate selection, or formal certainty grading. The tables are illustrative selections and cannot establish exposure prevalence, compare toxicity across drug classes, or identify a universal dose regimen.
For the orthomolecular perspective, the author’s existing I-OM nutrient monographs were additionally inspected in the live I-OM.ai Global knowledge collection on 11 November 2026 [5]. These internal records include proposed clinical ranges, historical orthomolecular experience, and research hypotheses. They are treated as author perspective, not as independent clinical evidence. Where a monograph gives a range without traceable underlying cases, the range is attributed to the compendium and is not described as a verified maximum or established safety window. The source inventory is reproduced in Appendix A to make the author perspective inspectable without access to the private collection.
OpenAI ChatGPT supported source discovery, drafting, editing, and reference organization. I-OM.ai doctrines and principles informed the conceptual framework. The declaration below distinguishes these contributions; this preparation did not include an independent external peer review.
Four descriptive evidence categories are used: established deficiency treatment or recognized clinical toxicity; indication-specific human intervention evidence; preliminary human or observational evidence; and experimental mechanistic evidence. These are editorial categories, not formal GRADE ratings. Biochemical necessity does not establish an effective supplemental dose in a nutrient-replete person. Similarly, an experimental reduction in respiration does not by itself establish net clinical harm from a medication.
The intended population is adults with acquired risk factors or suspected nutrient insufficiency. Primary mitochondrial disease is discussed where it provides relevant examples, but its treatment regimens should not be generalized to healthy aging. Numerical doses below describe selected clinical uses or research exposures, rather than a combined prescription. The synthesis focuses on adults; pediatric, pregnancy, critical-care, and inherited-disease regimens require their own evidence and clinical guidance.

3. A Systems View of Mitochondrial Vulnerability

3.1. Cofactors and Metabolic Bottlenecks

Thiamine-derived thiamine diphosphate supports pyruvate and alpha-ketoglutarate dehydrogenase reactions. Riboflavin supplies flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD); niacin supplies nicotinamide adenine dinucleotide (NAD)-related cofactors; pantothenate supplies coenzyme A. Magnesium is required for ATP-related reactions. Iron and copper contribute to respiratory proteins, while selenium supports selenoprotein-dependent redox defense. These functions explain why deficiency can impair metabolism; they do not establish that excess intake increases pathway flux once another step becomes limiting.
Vitamin B12 has a particularly relevant mitochondrial role through methylmalonyl-CoA mutase. Vitamin C supports carnitine biosynthesis and other enzyme systems, in addition to aqueous antioxidant chemistry. Zinc and copper balance matters because excess zinc can induce copper deficiency, potentially compromising hematological and neurological function [6,7,8,9,10,11,12,13].

3.2. Injury is Dependent on Concentration and Susceptibility

Respiratory inhibition, membrane disruption, mitochondrial translation defects, and disturbed redox control represent different injuries. Risk depends on tissue exposure, duration, clearance, age, genetic susceptibility, and concurrent disease. A pharmacological action can also be beneficial at one exposure and harmful at another. Renal impairment, drug interactions, or acute illness may convert a tolerated regimen into a hazardous one.
Reactive oxygen species also participate in adaptation. A small human exercise study found that combined vitamin C and vitamin E supplementation attenuated selected training-associated metabolic responses [14]. This finding does not establish that all antioxidants impair exercise; it demonstrates why lowering an oxidative marker cannot automatically be equated with improved health.

4. Common and Underrecognized Stressors

4.1. Tobacco Smoke and Particulate Pollution

Smoking is an actionable mitochondrial exposure. A small human study found lower platelet complex I activity in smokers than nonsmokers [15]. Its tissue and sample-size limitations preclude inference about every organ, but it supplies direct human biochemical evidence beyond cell-culture plausibility.
Particulate air pollution has been associated with altered leukocyte mitochondrial DNA copy number in observational research [16]. Copy number is influenced by cellular composition and compensatory responses and is not a direct measurement of ATP production. The practical implication is exposure reduction where feasible, including smoke avoidance and attention to indoor and occupational air quality; antioxidant supplements should not be represented as a substitute.

4.2. Pesticides and Metals

Rotenone inhibits complex I, whereas paraquat promotes redox stress through distinct chemistry. In an Agricultural Health Study nested case-control analysis, reported use of these pesticides was associated with Parkinson disease [17]. The study supports concern but cannot prove that a particular exposure caused disease in an individual. Occupational exposure is also not interchangeable with trace dietary residue exposure.
Cadmium, lead, mercury, and arsenic merit inclusion in a clinical exposure history when occupation, contaminated water, tobacco, or a specific incident makes exposure plausible. Experimental mitochondrial effects should be interpreted alongside validated toxicological assessment. This review does not infer that nonspecific fatigue establishes metal poisoning. Empirical chelation or nonspecific “detoxification” is not an evidence-based mitochondrial nutrition strategy.

4.3. Sleep Restriction and Insufficient Physical Activity

Sleep loss is a physiological stressor rather than a chemical toxicant. An experimental study in young men reported reduced muscle mitochondrial respiration after five nights of restricted sleep [18]. Human training research also demonstrates that exercise can improve skeletal-muscle mitochondrial respiration, with effects dependent on training modality [4]. These findings make sleep and activity relevant to the same clinical assessment as nutrition.
Chronic energy imbalance, insulin resistance, inadequate protein or energy intake, and persistent illness can alter metabolic demand and recovery. They should be evaluated without assuming that every associated symptom is mitochondrial in origin. Low-carbohydrate or ketogenic diets may change substrate use and may have specific clinical indications, but ketone production is not proof of universally improved mitochondrial function. Restrictive diets and fasting should preserve micronutrient adequacy and be adapted to frailty, illness, and metabolic risk.

4.4. Alcohol and Nutritional Compromise

Heavy alcohol exposure deserves attention both as a toxicological problem and as a cause of nutritional inadequacy, especially thiamine deficiency. In a patient with malnutrition, neurological findings, or refeeding risk, routine oral supplement doses may be inadequate. Suspected Wernicke encephalopathy requires urgent clinical treatment; an oral mitochondrial supplement regimen should not delay it [6].

5. Medications and Mitochondrial Risk

Medication review should distinguish direct mitochondrial effects, nutrient depletion, and proven adverse clinical outcomes. A drug’s therapeutic benefit, alternatives, and the consequences of untreated disease remain central. The categories in Table 1 do not imply a recommendation to stop prescribed treatment.
Table 1 covers 14 therapeutic groups with published mitochondrial findings, including adverse effects and a separately identified mechanistic example. Antibiotics remain combined. The examples span routine outpatient treatment, procedural care, and specialist therapy; they are not ranked by prescribing frequency or toxicity. Inclusion does not establish that the effect is frequent or causally responsible for symptoms during routine treatment.
Evidence key: Human denotes findings measured in patients or volunteers, including analysis of their tissues after clinical exposure. Experimental denotes cultured cells, isolated mitochondria, or animals. Human cells exposed to a drug in a laboratory count as experimental evidence. Observational patient findings do not by themselves establish drug causality.
Mitochondrial effects vary with dose, duration, tissue, and patient susceptibility and do not by themselves determine a therapy’s overall benefit–risk balance. Experimental respiratory inhibition, human biochemical changes, and clinically manifest organ injury are distinct levels of evidence. Metformin is retained explicitly as a mechanistic comparator rather than equated with documented destructive mitochondrial toxicity. For drugs with therapeutic benefit, mitochondrial findings should inform risk assessment, monitoring, and research rather than automatic discontinuation.

5.1. Antibiotics and Mitochondrial Translation

The evolutionary relationship between bacterial and mitochondrial translation provides a plausible off-target mechanism, but antibiotic classes cannot be treated as interchangeable. Linezolid-associated mitochondrial protein synthesis inhibition has direct clinical tissue support [25]. Aminoglycoside-associated deafness in susceptible mitochondrial ribosomal genotypes illustrates how genetics can strongly modify risk [26]. These examples support careful agent selection and monitoring without implying that all antibiotic use causes persistent mitochondrial disease.

5.2. Nutrient Depletion May be More Actionable than Speculative Toxicity

A randomized trial of long-term metformin treatment documented increased vitamin B12 deficiency [41]. This is a clinically actionable pathway that can be assessed and treated. Acid-suppressing therapy can also affect B12 availability, while long-term proton pump inhibitor use can cause hypomagnesemia in susceptible individuals [8,9]. A supplement alone may not resolve a continuing medication-related absorption problem.
Statin-associated symptoms require differential diagnosis, review of interacting drugs, and individualized lipid-lowering management. Coenzyme Q10 depletion is biologically plausible, but supplementation is not established as a universal preventive strategy for statin symptoms. Randomized evidence on symptom attribution is essential to avoid misclassifying common background muscle pain as drug injury [42].

5.3. Human Biochemical Findings and Clinical Outcomes

Ryan et al. followed eight adults receiving atorvastatin 80 mg/day for eight weeks and reported a progressive reduction in muscle mitochondrial oxidative phosphorylation capacity exceeding 30% [19]. The lack of myalgia and absence of a significant group change in maximal aerobic capacity illustrate that a tissue bioenergetic endpoint is not interchangeable with symptomatic toxicity. This small before-and-after study complements, rather than replaces, randomized evidence on statin symptoms and cardiovascular outcomes [42].
Chronic corticosteroid treatment was associated with lower complex-I activity and greater oxidative DNA damage in biopsied muscle [24]. Propofol infusion syndrome and acetaminophen overdose represent different exposure contexts with clinically manifest severe toxicity [22,36]. Grouping these observations is useful for identifying pathways, but they do not justify assigning the same risk to a short corticosteroid course, routine analgesic dosing, or brief sedation.

5.4. Implications for Nutrient Support

These findings do not establish that a single nutrient regimen prevents medication-related mitochondrial injury. A documented nutrient deficit, such as metformin-associated B12 depletion, supplies a more direct treatment target than a mechanistic laboratory finding alone. Pharmacological rescue of overdose, specialist management of organ toxicity, and routine nutrient supplementation are different interventions. In oncology, cardioprotection and supplement use require assessment within the anticancer regimen; nutrients should not be presumed to preserve efficacy or prevent cardiotoxicity without relevant evidence.

6. Orthomolecular Dosing as a Context Dependent Strategy

Orthomolecular dosing treats nutrients as active tools for improving function. Preventing deficiency is a necessary starting point, but it does not answer the therapeutic question: what exposure best supports metabolism in this patient, under these conditions? A recommended dietary allowance addresses nutritional adequacy in generally healthy populations; it was not designed to identify the dose that improves a disease-related metabolic constraint. The I-OM task is to connect nutrient availability to function, then establish a useful dose through indication-specific evidence, measured response, and safety assessment.
An I-OM strategy identifies a metabolic bottleneck and selects the nutrient, formulation, route, and exposure capable of addressing it. Higher doses have therapeutic precedents in impaired absorption, transport, and cofactor-responsive disease [43,44,45]. These precedents motivate broader investigation of acquired metabolic stress and aging. Baseline status, intended functional outcome, duration, interactions, and stopping criteria make this approach clinically assessable rather than an exercise in maximizing intake.
The I-OM Nutrient Prioritization Principle places essential nutrient adequacy first, followed by other compounds with relevant evidence of benefit. Dose is considered separately: an essential nutrient may require nutritional provision in one person and higher-dose treatment in another, according to metabolic context, evidence, response, and safety. The framework does not presume that all listed nutrients are limiting in every patient.
Table 2 places the recovered I-OM higher-dose ranges directly alongside published intervention results, documented adverse exposures, and functional-dose research opportunities. Appendix A provides a dated transcription summary of the broader author-recorded inventory and identifies unresolved source claims [5]. Population intake limits are not treated as toxic-dose thresholds. A documented adverse dose likewise does not mean that every lower dose is safe or that a therapeutic dose and a toxic exposure are separated by a fixed boundary.
Adult oral doses unless specified; mineral amounts are elemental. Studied doses are not necessarily minimum effective doses. This is a selected list of 15 entries, not a complete essential-nutrient inventory.

6.1. Interpreting Author Recorded Dose Ranges

Table 2 keeps the author-recorded I-OM ranges visible beside the published evidence, rather than allowing a familiar trial dose to become an assumed ceiling. For example, the recorded riboflavin range is 200–800+ mg/day; the 400 mg/day migraine regimen is one studied exposure, not a maximum [5,50]. An author-recorded range identifies a proposition to evaluate. It does not establish benefit across that range or justify escalation without a defined indication.
Appendix A preserves the broader inventory as a dated transcription summary [5]. It separates proposed ranges from unverified historical upper-exposure claims. Most monographs leave higher dosing individualized without specifying a numerical maximum. A plus sign therefore means that the source gives no fixed ceiling; it supplies no evidence of unlimited benefit or safety. The private monographs are the source of the author’s perspective, not independent validation of it.
The research objective is to locate a favorable benefit–harm range for a specified population, formulation, route, and outcome. Deficiency correction, functional benefit, biochemical disturbance, clinical adverse effects, and overt poisoning can occur at different exposures. Neither an upper intake limit nor the highest tolerated case report alone establishes an optimum.

6.2. B Vitamins and Cofactor Responsive Conditions

Preventing deficiency and optimizing function are distinct therapeutic objectives. Essential nutrient adequacy is the starting point; selected higher-dose interventions may address absorption, transport, or utilization constraints beyond those captured by routine intake targets. Thiamine needs should be considered in malnutrition, alcohol-related disease, persistent vomiting, and refeeding. Low carbohydrate intake does not abolish thiamine requirements. Riboflavin-responsive inherited disease provides a strong example of high-dose treatment selected by diagnosis; it does not demonstrate that 400 mg/day improves mitochondrial function in a riboflavin-replete adult [6,7,80].
The author-recorded I-OM clinical riboflavin range is 200–800+ mg/day, with higher individualized dosing left open for selected clinical contexts [5]. The 400 mg/day migraine regimen is not a maximum-dose boundary. Whether increasing exposure above that regimen adds mitochondrial or clinical benefit depends on the condition and requires an active-dose comparison. A clinical series of 31 patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency reported symptom improvement with riboflavin treatment [43]. This demonstrates that a vitamin can act as a targeted metabolic treatment in a responsive phenotype. The enzyme-cofactor affinity model discussed by Ames and colleagues explains why higher cofactor availability can be therapeutically relevant [44]. Extending this principle to acquired metabolic stress is a priority for testing, with responder selection and dose–response evidence central to the study design.
A dose-finding trial in 120 older adults with mild B12 deficiency tested 2.5–1000 micrograms/day for 16 weeks. Modeling estimated that 647–1032 micrograms/day produced 80–90% of the maximal methylmalonic-acid reduction [45]. These modeled values illustrate a replacement requirement far above ordinary dietary provision. They were not separately randomized dose groups; broader functional optimization requires its own dose comparison.

6.3. Niacin and NAD Precursors

Nicotinic acid, nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide differ in pharmacology and evidence. In a small study of adult-onset mitochondrial myopathy, escalating niacin increased NAD-related measures and was associated with improved muscle outcomes [51]. This is a direct human precedent for targeting mitochondrial metabolism with a vitamin; controlled studies are needed to define the dose response and extend its application.
By contrast, a randomized trial of nicotinamide riboside at 2000 mg/day for 12 weeks in obese insulin-resistant men did not improve insulin sensitivity or whole-body glucose metabolism [81]. A small trial of nicotinamide mononucleotide in prediabetic women reported improved muscle insulin sensitivity [82]. Together, these results make metabolic context a central design variable: select patients with a plausible NAD-related constraint, establish exposure, and test whether functional benefits follow. Circulating NAD-related metabolites should support that assessment alongside clinical outcomes.

6.4. Vitamin C as an Active Mitochondrial and Systemic Intervention

Vitamin C merits priority in mitochondrial care because its redox and cofactor functions connect cellular protection, substrate handling, and physiological recovery. In experimental work, mitochondrial uptake of dehydroascorbate and its reduction to ascorbate were associated with reduced mitochondrial reactive oxygen species, less oxidative mitochondrial DNA damage, and protection against membrane depolarization [54]. These findings provide a direct mitochondrial rationale for intervention. Together with vitamin C’s roles in carnitine-related enzymology and systemic redox regulation, they justify investigating whether greater availability improves function during illness, toxicant exposure, or increased metabolic demand [11]. The experimental findings establish biological plausibility; they do not identify an effective human oral dose.
The author’s I-OM clinical perspective includes oral vitamin C at 10–15 g/day in divided doses, individualized to clinical context and tolerability. The broader monograph records selected therapeutic oral use exceeding 10–50+ g/day [5]; the different ranges describe different contexts rather than a single recommended ceiling. This practice range is presented transparently as an author-proposed approach, not a dose established by controlled trials to optimize mitochondrial function or healthy longevity. This proposed range warrants direct study for acquired metabolic stress and increased physiological demand. Trials should compare this range with lower active doses and determine whether changes in tissue availability, redox state, fatigue, exercise tolerance, or mitochondrial oxidative function translate into meaningful benefit. Renal impairment, a history of oxalate stones, iron overload, concurrent treatment, formulation, and gastrointestinal effects affect patient selection and dosing [11].
Healthy-volunteer plasma saturation is not a demonstrated ceiling on therapeutic benefit. Oral absorption, tissue uptake, turnover, and clearance are different processes. Nonlinear oral pharmacokinetics describe exposure; they do not alone establish the optimal dose under disease or stress [56,57]. Conversely, declining fractional absorption cannot be ignored when choosing a regimen. Divided-dose oral treatment and intravenous administration should be evaluated as distinct interventions. At 1.25 g, measured mean peak plasma concentrations were approximately 135 µmol/L orally and 885 µmol/L intravenously; substantially higher IV exposures were predicted at larger doses [56]. Those exposure differences explain why a result obtained by one route cannot simply be assigned to the other.
Human findings give this agenda a clinical starting point. A randomized study of 141 analyzed office workers found that a single 10-g IV dose reduced current fatigue ratings over the following day, with a stronger signal in the lower-baseline-vitamin-C subgroup [55]. It did not measure mitochondrial function or establish benefit from chronic oral 10–15 g/day. An oral 10-g/day trial in advanced colorectal cancer found no improvement in progression or survival [83], showing that high-dose exposure alone does not guarantee efficacy in a different clinical setting. The appropriate next step is targeted dose–response research, with route, baseline status, metabolic demand, and functional outcomes specified in advance.
The practical I-OM position is to treat vitamin C as a serious therapeutic candidate whose dose deserves investigation beyond deficiency prevention. Clinical response, gastrointestinal tolerability, and renal and other relevant safety measures should be assessed together; bowel tolerance alone cannot establish tissue need or long-term safety [11]. Evidence from primary inherited mitochondrial disease [80] should inform that specific indication without being used to close the broader question of acquired metabolic stress. The central challenge is to establish which patients benefit from higher exposure, how much they need, and whether benefits persist.

6.5. Minerals as Metabolic Partners in Orthomolecular Treatment

Magnesium is a central partner in orthomolecular treatment because ATP-dependent reactions require appropriate magnesium availability. Its functional importance extends beyond achieving a serum result within a reference interval. A trial in normomagnesemic insulin-resistant adults found improvements in selected metabolic outcomes with supplementation [58]. This supports studying functional responses alongside conventional assessment; intracellular tests themselves still require clinical validation [9].
Trace elements offer targeted opportunities: selenium supports redox enzymes, zinc supports protein and cellular maintenance, copper supplies complex IV, and iron supports respiratory proteins and oxygen delivery [12,13,67,73]. Their benefit depends on coordinated availability. High zinc exposure can impair copper status, and excess iron or copper can increase injury. The I-OM aim is to improve a limiting pathway while preserving its nutritional partners. Copper-associated cirrhosis after 30–60 mg/day for three years is a documented case exposure, not an experimentally defined minimum toxic dose [68]. Acute iron poisoning thresholds refer to single ingestions and cannot be substituted for chronic supplementation safety [73].

6.6. Adverse Effects and Toxicity Are Different Dose Endpoints

The safety column distinguishes biochemical changes, clinical adverse outcomes, and overt poisoning. In a three-year vitamin D trial in 311 adults, 4000 and 10000 IU/day were associated with lower radial volumetric bone density than 400 IU/day, without a significant between-group difference in estimated bone strength [63]. This does not define a universal poisoning dose. Similarly, SELECT found more alopecia with a 200 microgram/day selenium supplement, while EFSA contextualized this as an estimated total intake near 330 micrograms/day [70,71].
For niacin, formulation matters: sustained-release products have a different hepatotoxicity profile from immediate-release and prescription extended-release preparations [53]. The overlap between therapeutic doses and reported adverse exposures makes monitoring essential; it does not invalidate all higher-dose therapy. “Not established” in Table 2 denotes uncertainty about a reliable general toxic-dose threshold, not evidence that a nutrient is harmless at every dose.

6.7. Beyond Deficiency Prevention and the I-OM Functional Dose Hypothesis

A central I-OM proposition is that the intake needed to prevent overt deficiency may differ from the exposure needed to improve function under a particular metabolic constraint. Routine nutrient concentrations and population intake targets do not directly measure intracellular cofactor availability or enzyme performance. The proposed functional-dose hypothesis is that, in selected individuals, increasing nutrient availability above ordinary nutritional requirements may improve mitochondrial metabolism by overcoming impaired absorption or transport, reduced enzyme–cofactor affinity, or increased physiological demand. The cofactor-affinity model and vitamin-responsive disorders provide biological precedent [43,44]. Extension to common acquired disease or aging is a hypothesis requiring direct testing, rather than an established consequence of that precedent.
Testable hypothesis. Among patients with a specified metabolic constraint, a higher nutrient exposure may improve mitochondrial function and a relevant clinical outcome more than a lower active replacement dose, without a disproportionate increase in adverse effects. This proposition is not that all higher doses are better. A plateau, no between-dose benefit, or excess harm would argue against escalation in the population studied.
A useful study should predefine the suspected constraint, enroll separately characterized deficient and nondeficient participants, and compare at least two active doses with the same formulation and route. Where appropriate, a placebo or standard-care group can distinguish replacement benefit from additional dose benefit. Trials should pair a relevant mitochondrial measure, such as muscle oxidative capacity, with walking performance, strength, fatigue, or another prespecified clinical outcome. Nutrient exposure, adherence, concurrent treatments, adverse events, and withdrawal criteria should be recorded. Proposed high concentrations without preliminary safety and exposure data call for staged investigation rather than immediate efficacy trials.
Thiamine is a priority example. Its active cofactor supports pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, placing it at key points in mitochondrial substrate oxidation [6]. In a randomized crossover trial of 40 adults with quiescent inflammatory bowel disease and chronic fatigue, oral thiamine at 600–1800 mg/day for four weeks reduced fatigue compared with placebo; only mild side effects were detected [46]. This is a clinically relevant benefit at doses far above ordinary nutritional requirements. The trial did not measure mitochondrial respiration or compare several active dose levels, so it cannot identify the mechanism or establish that gram doses outperform lower therapeutic doses.
High oral doses are not necessarily excluded by saturable active absorption. A pharmacokinetic study using single doses of 100, 500, and 1500 mg found increasing systemic exposure, consistent with active and passive absorption [47]. However, greater circulating exposure does not establish greater intracellular thiamine diphosphate, mitochondrial enzyme flux, or clinical benefit. Historical Alzheimer studies administered 3–8 g/day; an exploratory report suggested possible benefit, whereas a small 12-month placebo-controlled study of 3 g/day did not slow cognitive decline [48,49]. A later trial of 600–1800 mg/day in primary biliary cholangitis also found no superiority to placebo for fatigue [84]. These findings support context-specific investigation rather than a universal gram-dose prescription.
The actionable research question is therefore whether higher thiamine exposure improves mitochondrial function in a biologically defined subgroup, and whether it adds benefit over a lower active dose. Studies should compare dose levels, characterize baseline nutritional and metabolic status, and pair cofactor measures with muscle oxidative function, exercise capacity, fatigue, and safety. Magnesium availability and other metabolic constraints should be assessed as potential modifiers. Thiamine hydrochloride, benfotiamine, and other derivatives require separate exposure and efficacy assessment. A reliable general oral toxic-dose threshold has not been established; this uncertainty cannot substitute for long-term safety evidence [6].
Vitamin D illustrates a different research boundary. The recorded I-OM perspective proposes serum 25(OH)D of 50–100 ng/mL for optimization and 100–150 ng/mL for selected supervised cases [5]. These are author-proposed targets; the hypothesis is that selected higher-demand phenotypes may gain additional function at higher exposure. A small before–after study in severely deficient adults associated treatment with improved skeletal-muscle mitochondrial oxidative function [62]. Whether higher serum 25-hydroxyvitamin D concentrations produce additional benefit is unresolved. Serum concentrations are exposure markers, not vitamin D3 doses. A universal therapeutic or safety window at 100–150 ng/mL has not been established: overt toxicity commonly involves levels above 150 ng/mL with hypercalcemia or hypercalciuria, while adverse outcomes may occur below overt-poisoning concentrations [63,64]. Current prevention guidance does not establish a universal optimal serum target [65]. Investigation of higher exposure would require a staged benefit–risk rationale and monitoring of calcium metabolism, urinary calcium, renal function, and skeletal outcomes, not simply absence of symptoms.
The I-OM research agenda is to identify the right nutrient, exposure, and metabolic context for functional benefit. Documented efficacy is a starting point for dose optimization, not proof that an optimum has been reached. Equally, a reported toxic exposure does not establish the safety or effectiveness of every lower exposure. Dose-ranging studies can determine whether additional benefit exists, where it plateaus, and which patients respond.

6.8. Extending Functional Dose Research Across Nutrients

The I-OM functional-dose proposition applies across nutrients, not only to thiamine and vitamin D. Table 2 therefore specifies higher oral or parenteral exposures, blood concentrations where informative, and the actual outcomes studied. Table 2 presents author-recorded ranges alongside their distinct published evidence; Appendix A records additional vitamins and related nutrients without implying established mitochondrial indications. The published examples include riboflavin at 400 mg/day, niacin at approximately 1 g/day in mitochondrial myopathy, ultrahigh-dose methylcobalamin in early ALS, route-dependent vitamin C exposure, creatine loading, and gram-level GlyNAC [50,51,56,59,77,78,79]. These data show that nutrient interventions can have biological and clinical effects beyond ordinary nutritional provision. They do not establish a shared optimal dose or a shared mechanism.
The strongest translational question is whether a higher exposure restores a limiting function in a defined metabolic context. The early-ALS methylcobalamin trial illustrates pharmacological nutrient treatment beyond routine deficiency replacement; its clinical result does not establish a mitochondrial mechanism [59]. In normomagnesemic insulin-resistant adults, magnesium improved selected metabolic outcomes, illustrating why a normal circulating result need not exclude a functional response [58]. Zinc-containing AREDS therapy and selenium treatment in mild Graves orbitopathy provide further disease-specific precedents; neither directly demonstrates mitochondrial enhancement [66,69]. Higher-dose CoQ10 in Parkinson disease and add-on niacin in statin-treated cardiovascular disease also show that plausible mechanisms and improved exposure or biomarkers can coexist with no added clinical benefit [52,75]. These differences make patient selection and dose comparison central to the I-OM research agenda.
A blood concentration is useful only in relation to the question it answers. It may reflect intake, recent administration, transport, storage, or clearance rather than mitochondrial availability. Vitamin C demonstrates that route can sharply alter plasma exposure [56]. For B12, functional markers such as methylmalonic acid may be more relevant to replacement response than maximizing total circulating B12 [45]. For iron, magnesium, zinc, copper, and selenium, accumulating circulating nutrient or stores is not itself the therapeutic objective [9,13,67,71,73]. No general high blood concentration targets have been validated for mitochondrial optimization across these agents. Research should measure relevant active cofactors or tissue processes where feasible and establish whether higher exposure adds functional benefit over a lower active dose. Positive, plateauing, and adverse dose responses are all informative.

8. A Practical Clinical Assessment Framework

The evidence supports different actions at different levels of certainty. Table 3 separates clinical treatment targets from hypotheses requiring further study. The I-OM framework connects these levels without treating them as equivalent.
The proposed I-OM Systems Medicine application follows four steps: divide the problem into exposures, nutrient constraints, and physiological demands; examine evidence for each; reconnect their interactions; and intervene against the most defensible targets. This organizing model is a clinical perspective, not a validated diagnostic algorithm.
First, establish the phenotype. Fatigue, pain, exercise intolerance, neuropathy, and cognitive complaints have many causes. Anemia, endocrine disease, cardiopulmonary disease, sleep disorders, depression, medication effects, and undernutrition should be considered before assigning a mitochondrial explanation.
Second, construct a timeline of prescriptions, supplements, smoking, occupational exposures, diet restriction, alcohol, infection, and symptom change. Medication-related nutrient depletion may have greater immediate clinical relevance than an unvalidated commercial mitochondrial score. Exposure testing should be selected from a plausible history, not ordered as an indiscriminate panel.
Third, assess likely constraints. Depending on the presentation, appropriate tests may include a blood count, renal and hepatic indices, electrolytes including magnesium, B12 with confirmatory testing when appropriate, and iron studies. Lactate is neither a sensitive nor a specific screening test for every mitochondrial disorder and is vulnerable to collection artifacts. Circulating mitochondrial DNA measures, NAD assays, and commercial organic-acid interpretations should not be treated as validated stand-alone dosing targets.
Fourth, define a limited intervention and a measurable outcome. Correct a credible deficiency, reduce avoidable exposure, and review implicated medications with the prescriber. Introduce higher-dose agents for a defined indication, record all concurrent products, and set a reassessment interval. Outcomes may include a relevant laboratory correction, walking capacity, strength, symptom burden, or treatment tolerance. Escalation without objective or patient-important benefit should trigger reconsideration rather than automatic addition of more supplements.
For example, a metformin-treated adult with new neuropathy warrants evaluation for B12 deficiency and other causes; this is more actionable than assuming generalized respiratory-chain poisoning. An adult taking several products containing B6 who develops sensory symptoms needs assessment for supplement toxicity. These examples show how “mitochondrial support” itself can become a source of harm if total exposure is ignored.

9. Research Priorities and Limitations

Future studies should distinguish nutrient-deficient participants from nutrient-replete participants and separate inherited mitochondrial disorders from acquired metabolic disease. Stratification by medication exposure, renal function, genotype where relevant, and metabolic status would improve interpretability. A trial of a multi-ingredient product without baseline characterization cannot readily identify which component helped, which was unnecessary, or which caused adverse effects.
Functional endpoints should accompany biochemical measurements. Muscle respiration, phosphocreatine recovery, exercise capacity, patient-reported function, and adverse events answer different questions. Changes in blood NAD, leukocyte mitochondrial DNA, or antioxidant capacity alone should not be marketed as restored organismal mitochondrial health.
Priority designs include comparisons of lower and higher active doses in patients with plausible functional constraints, including carefully characterized participants without overt deficiency; dose-ranging trials in biomarker-defined deficiency; pragmatic correction of medication-associated nutrient depletion; and factorial trials testing exposure reduction with or without targeted supplementation. Reporting should include formulation, actual nutrient content, adherence, concomitant treatment, and reasons for withdrawal.
This review is limited by targeted selection, heterogeneous populations, reliance on selected studies rather than exhaustive synthesis, and incomplete long-term dose-response data. Several environmental mechanisms remain supported primarily by experimental evidence. Some therapeutic dose examples are derived from clinical practice or small disease-specific studies. Table 2 and Appendix A include internal author-proposed ranges rather than independently evaluated guidelines. The monographs differ in completeness, and no exhaustive search for the highest-ever dose of every nutrient was performed. Historical upper-exposure claims require original-source appraisal before supporting clinical recommendations. Selection of positive mechanistic examples can exaggerate perceived risk, and publication bias may favor novel toxicity or supplementation findings. Studies of inherited disease, overdose, and high local drug concentrations have limited transferability to typical outpatient exposure. Conversely, absent population trials do not eliminate the value of correcting a specific deficiency or recognizing a documented drug reaction. No included supplement trial establishes human lifespan extension, and the combined I-OM strategy has not been tested as a package. The framework therefore generates testable clinical and research propositions; it does not establish a validated mitochondrial optimization protocol.

10. Conclusions

Mitochondrial care should reduce avoidable injury and actively address nutritional constraints on function. Environmental exposures, medication effects, nutrient depletion, sleep, and physical activity belong in the same clinical assessment. A laboratory mitochondrial effect should inform a therapy’s benefit–risk assessment rather than automatically prompt its withdrawal.
Preventing deficiency and optimizing function are different objectives. Higher orthomolecular doses have produced benefits in selected clinical settings, and cofactor-responsive disorders demonstrate that ordinary nutritional provision does not meet every functional requirement. The next question is when this principle extends to acquired metabolic stress and healthy aging. Thiamine, riboflavin, niacin, and other nutrients warrant direct comparisons of lower and higher active doses, with mitochondrial function and patient-important outcomes measured together.
The I-OM perspective makes its proposed ranges explicit and includes historical high-dose experience as a source of testable questions. Its strongest claim is the need to investigate functional requirements beyond deficiency prevention. Its ranges and highest reported exposures require indication-specific appraisal; they do not define universal safe ceilings. Vitamin D concentration targets, gram-level B-vitamin use, and multi-gram oral vitamin C should be evaluated with formulation, duration, physiological demand, and relevant safety measures specified. The goal is the exposure that improves function with an acceptable balance of benefit and harm. This approach offers a research framework for preserving resilience and healthspan; human lifespan extension remains unproven.

Author Contributions

Richard Z. Cheng developed the I-OM conceptual framework and prepared this manuscript. As sole author, he is responsible for its scientific content and conclusions.

Funding

No external funding supported this work.

Institutional Review Board Statement

Not applicable: no original human or animal participant research was conducted for this narrative review and conceptual manuscript.

Data Availability Statement

No original empirical dataset was generated or analyzed. Published sources are identified in the references. Author-recorded ranges in Table 2 are summarized from internal I-OM nutrient monographs [5]. Appendix A provides the selected dose inventory, source version, inspection date, transcription conventions, and unresolved historical claim so that readers can inspect the numerical propositions without access to the private platform. It is a transcription summary, not a release of complete original monographs or patient-level records. Underlying historical case reports not identified in the source remain unverified and are not used as evidence of efficacy or safety.

Acknowledgments

None.

Use of Generative AI

OpenAI ChatGPT and I-OM.ai assisted with literature discovery, manuscript organization, drafting, language editing, and bibliographic checks. I-OM.ai doctrines and principles guided the conceptual framework, and existing nutrient monographs were consulted for the attributed author perspective. The human author retains responsibility for verifying every citation, interpreting evidence, selecting conclusions, disclosing interests, and approving the final text. AI assistance is not evidence of external peer review.

Conflicts of Interest

Richard Z. Cheng is the founder of I-OM.ai and the developer of the I-OM conceptual framework discussed in this manuscript. He authored the internal nutrient monographs used to describe the I-OM dosing perspective. These roles constitute relevant professional and intellectual interests. No additional conflicts are declared.

Abbreviations

ATP, adenosine triphosphate; CoQ10, coenzyme Q10; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; GlyNAC, glycine plus N-acetylcysteine; I-OM, Integrative Orthomolecular Systems Medicine; NAD, nicotinamide adenine dinucleotide; NSAIDs, nonsteroidal anti-inflammatory drugs; OXPHOS, oxidative phosphorylation; ROS, reactive oxygen species. Gene symbols follow the cited sources.

Appendix A. Author Recorded I-OM Dose Inventory

Source and provenance. Selected dose entries summarized from Richard Z. Cheng’s I-OM Nutrient Monographs, Version 1.0, July 2026, in the private I-OM.ai Global knowledge collection; inspected 11 November 2026 [5]. This appendix records the numerical propositions used in this review. It is an edited transcription summary with review commentary, not a verbatim facsimile, complete monograph release, clinical guideline, or independently verified case series. Reproducing an author proposal makes it inspectable but does not validate it.
Transcription conventions. Unless a route or blood concentration is given, amounts represent the author’s recorded adult oral dosing perspective. Mineral quantities are elemental; vitamin D entries are serum 25(OH)D concentrations, not administered vitamin D3 doses. A plus sign preserves an open-ended range in the source and does not establish a maximum safe dose. Formulation, duration, population, and outcome are not uniformly documented across the source entries; missing details are not inferred. B8 is excluded because its nutrient identity was unresolved. This is a selected inventory rather than an exhaustive list of essential nutrients or the highest-ever exposures.
Table A1. Selected author-recorded ranges and their interpretation.
Table A1. Selected author-recorded ranges and their interpretation.
Nutrient or form Author-recorded range or source claim Interpretation for this review
Thiamine B1 Recorded clinical range 100–1,500+ mg/day; advanced dosing left individualized Author range; published 3–8 g/day exposures appear separately in Table 2 [48,49]. Formulations require separate evaluation.
Riboflavin B2 Recorded clinical range 200–800+ mg/day; advanced dosing left individualized 400 mg/day is a studied migraine regimen [50], not a maximum. Benefit above it remains context dependent.
Pantothenic acid B5 OM support 250–1,000 mg/day; further therapy individualized Author proposal; no general mitochondrial optimization dose is established by this review.
Vitamin B6 OM support 50–100 mg/day; further therapy individualized This proposed range overlaps reported neuropathy exposures [60]. It is not a safe maintenance range for every patient.
Biotin B7 OM support 1–10 mg/day; further therapy individualized Author proposal. General mitochondrial benefit and a safe ceiling are not established here; review potential laboratory-test interference.
Folate B9 OM support 1–5 mg/day; further therapy individualized Author proposal; specify folate form and assess B12 status. This review establishes no general mitochondrial optimization dose.
Vitamin B12 OM support 1–5 mg/day; further therapy individualized Author oral range. The 50 mg IM trial exposure in Table 2 is a separate route and indication [59].
Vitamin C Author practice example 10–15 g/day orally, divided; compendium therapeutic oral use may exceed 10–50+ g/day Distinguish proposed oral dosing from IV pharmacology. No numerical maximum is established by the compendium.
Vitamin D Proposed serum 25(OH)D 50–100 ng/mL; selected supervised cases 100–150 ng/mL Author concentration framework, not a validated universal safety or efficacy window. Absence of symptoms does not establish safety [63,64,65].
Vitamin A Recorded clinical range 10,000–30,000+ IU/day; advanced dosing individualized Author proposal. Preformed vitamin A and carotenoids require separate interpretation; liver and reproductive risks constrain use.
Vitamin E Recorded clinical range 400–1,200+ IU/day; advanced dosing individualized Author proposal; specify chemical form. The monograph identifies bleeding concerns with higher doses and anticoagulants.
Vitamin K2 MK-4 45 mg/day, commonly 15 mg three times daily, described as a Japanese osteoporosis regimen The monograph records a disease-specific regimen. It does not establish a mitochondrial enhancement dose or a maximum.
Vitamin K2 MK-7 Vascular-support range 360–1,000+ µg/day; further therapy individualized Author proposal with emerging evidence. Do not extrapolate the MK-4 dose to MK-7; vitamin K antagonist interactions matter.
Magnesium elemental Increased-demand range 1,000–2,000+ mg/day; more intensive oral or IV therapy individualized Author proposal, not a general maintenance prescription. Compound weight, elemental amount, route, renal clearance, and bowel effects differ [9].
Zinc elemental Recorded clinical range 40–75+ mg/day; further therapy individualized Author proposal overlapping copper-depletion exposures [13]. Duration and copper balance are essential.
Copper Recorded clinical range 3–5 mg/day; further therapy individualized Author proposal; no independent mitochondrial benefit is established for replete adults. Assess copper handling and interactions [67,68].
Selenium Recorded clinical range 300–400 µg/day; further therapy individualized Author proposal overlapping adverse-exposure contexts [70,71]. Total intake, baseline status, and chemical form require appraisal.
Iodine Recorded clinical range 3–12.5 mg/day; further therapy individualized Author proposal; thyroid physiology and susceptibility constrain use. This review establishes no mitochondrial optimization indication.
Coenzyme Q10 Recorded clinical range 300–1,200+ mg/day; further therapy individualized Author range; published studies at 1,200–2,400 mg/day did not show Parkinson benefit [75]. Higher exposure requires an indication.
Creatine Recorded clinical range 10–20 g/day; further therapy individualized Author range. Separate brief loading or acute exposure from long-term treatment [77,78].
Taurine Recorded clinical range 6–10 g/day; further therapy individualized Author proposal; no general human mitochondrial enhancement dose or maximum is established here.
Alpha-lipoic acid Recorded clinical range 600–1,200+ mg/day; further therapy individualized Author range; the neuropathy evidence discussed in the main text concerns a specific condition [85].
Omega-3 EPA plus DHA Recorded clinical range 2–6+ g/day; further therapy individualized Author range; specify EPA/DHA composition, indication, concomitant treatment, and duration. A general mitochondrial optimum is not established.
Inventory interpretation. These entries preserve the author’s proposed research agenda. They are not a combined prescription. The published studies in Table 2 and the main text supply the separately cited clinical evidence. Proposed ranges that overlap documented adverse exposures require explicit benefit–risk justification; supervision or absence of symptoms alone does not establish safety. For biotin, laboratory-test interference must be considered; for vitamin K, interactions with vitamin K antagonists require attention. Additional entries without a reviewed mitochondrial intervention study are included solely to document the author’s perspective.
A1 Unverified historical exposure claim
The B3 monograph records 3–18 g/day as historical orthomolecular exposure, in addition to its author-recorded clinical range of 500–3,000 mg/day [5]. The original report establishing the upper figure was not available for appraisal, and its formulation, route, duration, population, clinical outcomes, and adverse events remain unresolved. This is a source-verification entry, not a documented highest administered dose, a safety window, or evidence supporting treatment at 18 g/day. It is excluded from the efficacy and safety argument. Verification would require the original report and its exposure details before the claim could be promoted to a clinical evidence entry.

References

  1. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. Hallmarks of aging: An expanding universe. Cell 2023, 186, 243–278. [Google Scholar] [CrossRef] [PubMed]
  2. Trifunovic, A.; Wredenberg, A.; Falkenberg, M.; et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429, 417–423. [Google Scholar] [CrossRef] [PubMed]
  3. Mau, T.; Barnes, H.N.; Blackwell, T.L.; et al. Lower muscle mitochondrial energetics is associated with greater phenotypic frailty in older women and men: The Study of Muscle, Mobility and Aging. Geroscience 2024, 46, 2409–2424. [Google Scholar] [CrossRef] [PubMed]
  4. Robinson, M.M.; Dasari, S.; Konopka, A.R.; et al. Enhanced protein translation underlies improved metabolic and physical adaptations to different exercise training modes in young and old humans. Cell Metab. 2017, 25, 581–592. [Google Scholar] [CrossRef] [PubMed]
  5. Cheng, R.Z. I-OM Nutrient Monographs. Version 1.0, July 2026. Internal author-compiled knowledge documents in the I-OM.ai Global collection, including vitamin and related nutrient dosing entries; unpublished author perspective, private collection inspected 11 November 2026. Selected dose entries and source limitations are reproduced as a transcription summary in Appendix A; the complete original collection is not publicly accessible. [PubMed]
  6. National Institutes of Health; Office of Dietary Supplements. Thiamin Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Thiamin-HealthProfessional/ (accessed on 10 November 2026).
  7. National Institutes of Health; Office of Dietary Supplements. Riboflavin Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/ (accessed on 10 November 2026).
  8. National Institutes of Health; Office of Dietary Supplements. Vitamin B12 Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/ (accessed on 10 November 2026).
  9. National Institutes of Health; Office of Dietary Supplements. Magnesium Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/ (accessed on 10 November 2026).
  10. National Institutes of Health; Office of Dietary Supplements. Vitamin B6 Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/ (accessed on 10 November 2026).
  11. National Institutes of Health; Office of Dietary Supplements. Vitamin C Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ (accessed on 10 November 2026).
  12. National Institutes of Health; Office of Dietary Supplements. Selenium Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/ (accessed on 10 November 2026).
  13. National Institutes of Health; Office of Dietary Supplements. Zinc Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/ (accessed on 10 November 2026).
  14. Ristow, M.; Zarse, K.; Oberbach, A.; et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA 2009, 106, 8665–8670. [Google Scholar] [CrossRef] [PubMed]
  15. Smith, P.R.; Cooper, J.M.; Govan, G.G.; Harding, A.E.; Schapira, A.H. Smoking and mitochondrial function: A model for environmental toxins. Q. J. Med. 1993, 86, 657–660. [Google Scholar] [CrossRef] [PubMed]
  16. Wang, X.; Hart, J.E.; Liu, Q.; Wu, S.; Nan, H.; Laden, F. Association of particulate matter air pollution with leukocyte mitochondrial DNA copy number. Environ. Int. 2020, 141, 105761, Corrigendum: Environ. Int. 2020, 143, 106069. https://doi.org/10.1016/j.envint.2020.106069. [Google Scholar] [CrossRef]
  17. Tanner, C.M.; Kamel, F.; Ross, G.W.; et al. Rotenone, paraquat, and Parkinson’s disease. Environ. Health Perspect.;PubMed 2011, 119, 866–872. Available online: https://pubmed.ncbi.nlm.nih.gov/21269927/. [CrossRef] [PubMed]
  18. Saner, N.J.; Lee, M.J.C.; Kuang, J.; et al. Exercise mitigates sleep-loss-induced changes in glucose tolerance, mitochondrial function, sarcoplasmic protein synthesis, and diurnal rhythms. Mol. Metab. 2021, 43, 101110. [Google Scholar] [CrossRef] [PubMed]
  19. Ryan, T.E.; Torres, M.J.; Lin, C.T.; et al. High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans. JCI Insight 2024, 9, e174125. [Google Scholar] [CrossRef] [PubMed]
  20. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348, 607–614. Available online: https://pubmed.ncbi.nlm.nih.gov/10839993/. [CrossRef]
  21. Fontecha-Barriuso, M.; Martín-Sanchez, D.; Martinez-Moreno, J.M.; et al. Molecular pathways driving omeprazole nephrotoxicity. Redox Biol. 2020, 32, 101464. [Google Scholar] [CrossRef] [PubMed]
  22. McGill, M.R.; Sharpe, M.R.; Williams, C.D.; Taha, M.; Curry, S.C.; Jaeschke, H. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J. Clin. Invest. 2012, 122, 1574–1583. [Google Scholar] [CrossRef] [PubMed]
  23. Krause, M.M.; Brand, M.D.; Krauss, S.; et al. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum. 2003, 48, 1438–1444. [Google Scholar] [CrossRef] [PubMed]
  24. Mitsui, T.; Azuma, H.; Nagasawa, M.; et al. Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J. Neurol. 2002, 249, 1004–1009. [Google Scholar] [CrossRef] [PubMed]
  25. De Vriese, A.S.; Van Coster, R.; Smet, J.; et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 2006, 42, 1111–1117. [Google Scholar] [CrossRef] [PubMed]
  26. Prezant, T.R.; Agapian, J.V.; Bohlman, M.C.; et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat. Genet. 1993, 4, 289–294. [Google Scholar] [CrossRef] [PubMed]
  27. Moullan, N.; Mouchiroud, L.; Wang, X.; et al. Tetracyclines disturb mitochondrial function across eukaryotic models: A call for caution in biomedical research. Cell Rep. 2015, 10, 1681–1691. [Google Scholar] [CrossRef] [PubMed]
  28. Hangas, A.; Aasumets, K.; Kekäläinen, N.J.; et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2. Nucleic Acids Res. 2018, 46, 9625–9636. [Google Scholar] [CrossRef] [PubMed]
  29. Kudin, A.P.; Mawasi, H.; Eisenkraft, A.; Elger, C.E.; Bialer, M.; Kunz, W.S. Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of alpha-lipoamide dehydrogenase. Int. J. Mol. Sci. 2017, 18, 1912. [Google Scholar] [CrossRef] [PubMed]
  30. DailyMed. Valproic Acid Capsules Prescribing Information. Available online: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df742f4a-9440-538d-e053-2a95a90a1de6 (accessed on 10 November 2026).
  31. Li, Y.; Couch, L.; Higuchi, M.; Fang, J.L.; Guo, L. Mitochondrial dysfunction induced by sertraline, an antidepressant agent. Toxicol. Sci. 2012, 127, 582–591. [Google Scholar] [CrossRef] [PubMed]
  32. Hedberg-Oldfors, C.; Lindgren, U.; Visuttijai, K.; et al. Lipid storage myopathy associated with sertraline treatment is an acquired mitochondrial disorder with respiratory chain deficiency. Acta Neuropathol. 2024, 148, 73. [Google Scholar] [CrossRef] [PubMed]
  33. Modica-Napolitano, J.S.; Lagace, C.J.; Brennan, W.A.; Aprille, J.R. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch. Pharm. Res. 2003, 26, 951–959. [Google Scholar] [CrossRef] [PubMed]
  34. Scaini, G.; Quevedo, J.; Velligan, D.; Roberts, D.L.; Raventos, H.; Walss-Bass, C. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur. Neuropsychopharmacol. 2018, 28, 369–380. [Google Scholar] [CrossRef] [PubMed]
  35. Krajčová, A.; Němcová, V.; Halačová, M.; Waldauf, P.; Balík, M.; Duška, F. Amiodarone but not propafenone impairs bioenergetics and autophagy of human myocardial cells. Toxicol. Appl. Pharmacol. 2023, 477, 116676. [Google Scholar] [CrossRef] [PubMed]
  36. Vollmer, J.P.; Haen, S.; Wolburg, H.; et al. Propofol related infusion syndrome: Ultrastructural evidence for a mitochondrial disorder. Crit. Care Med. 2018, 46, e91–e94. [Google Scholar] [CrossRef] [PubMed]
  37. Grishko, V.; Xu, M.; Wilson, G.; Pearsall, A.W., IV. Apoptosis and mitochondrial dysfunction in human chondrocytes following exposure to lidocaine, bupivacaine, and ropivacaine. J. Bone Jt. Surg. Am. 2010, 92, 609–618. [Google Scholar] [CrossRef] [PubMed]
  38. Cela, O.; Piccoli, C.; Scrima, R.; et al. Bupivacaine uncouples the mitochondrial oxidative phosphorylation, inhibits respiratory chain complexes I and III and enhances ROS production: Results of a study on cell cultures. Mitochondrion 2010, 10, 487–496. [Google Scholar] [CrossRef] [PubMed]
  39. Ichikawa, Y.; Ghanefar, M.; Bayeva, M.; et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 2014, 124, 617–630. [Google Scholar] [CrossRef] [PubMed]
  40. Zhang, S.; Liu, X.; Bawa-Khalfe, T.; et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18, 1639–1642. [Google Scholar] [CrossRef] [PubMed]
  41. de Jager, J.; Kooy, A.; Lehert, P.; et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ 2010, 340, c2181. [Google Scholar] [CrossRef] [PubMed]
  42. Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: An individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 2022, 400, 832–845. [CrossRef] [PubMed]
  43. Zhang, J.; Han, J.; Wang, Y.; et al. Characterization of 31 patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Balk. Med. J. 2022, 39, 290–296. [Google Scholar] [CrossRef] [PubMed]
  44. Ames, B.N.; Elson-Schwab, I.; Silver, E.A. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): Relevance to genetic disease and polymorphisms. Am. J. Clin. Nutr. 2002, 75, 616–658. [Google Scholar] [CrossRef] [PubMed]
  45. Eussen, S.J.P.M.; et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: A dose-finding trial. Arch. Intern. Med. 2005, 165, 1167–1172. [Google Scholar] [CrossRef] [PubMed]
  46. Bager, P.; Hvas, C.L.; Rud, C.L.; Dahlerup, J.F. Randomised clinical trial: High-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease. Aliment. Pharmacol. Ther. 2021, 53, 79–86. [Google Scholar] [CrossRef] [PubMed]
  47. Smithline, H.A.; Donnino, M.; Greenblatt, D.J. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin. Pharmacol. 2012, 12, 4. [Google Scholar] [CrossRef] [PubMed]
  48. Meador, K.; Loring, D.; Nichols, M.; et al. Preliminary findings of high-dose thiamine in dementia of Alzheimer’s type. J. Geriatr. Psychiatry Neurol. 1993, 6, 222–229. [Google Scholar] [CrossRef] [PubMed]
  49. Nolan, K.A.; Black, R.S.; Sheu, K.F.; Langberg, J.; Blass, J.P. A trial of thiamine in Alzheimer’s disease. Arch. Neurol. 1991, 48, 81–83. Available online: https://pubmed.ncbi.nlm.nih.gov/1986730/. [CrossRef] [PubMed]
  50. Schoenen, J.; Jacquy, J.; Lenaerts, M. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology 1998, 50, 466–470. [Google Scholar] [CrossRef] [PubMed]
  51. Pirinen, E.; Auranen, M.; Khan, N.A.; et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab. 2020, 31, 1078–1090.e5. [Google Scholar] [CrossRef] [PubMed]
  52. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365, 2255–2267. [Google Scholar] [CrossRef] [PubMed]
  53. National Institute of Diabetes and Digestive and Kidney Diseases. Niacin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Available online: https://www.ncbi.nlm.nih.gov/books/NBK548176/ (accessed on 10 November 2026).
  54. Kc, S.; Cárcamo, J.M.; Golde, D.W. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J. 2005, 19, 1657–1667. [Google Scholar] [CrossRef] [PubMed]
  55. Suh, S.-Y.; Bae, W.K.; Ahn, H.-Y.; Choi, S.-E.; Jung, G.-C.; Yeom, C.H. Intravenous vitamin C administration reduces fatigue in office workers: A double-blind randomized controlled trial. Nutr. J. 2012, 11, 7. [Google Scholar] [CrossRef] [PubMed]
  56. Padayatty, S.J.; Sun, H.; Wang, Y.; et al. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann. Intern. Med. 2004, 140, 533–537. [Google Scholar] [CrossRef] [PubMed]
  57. Levine, M.; Conry-Cantilena, C.; Wang, Y.; et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. USA 1996, 93, 3704–3709. [Google Scholar] [CrossRef] [PubMed]
  58. Mooren, F.C.; Krüger, K.; Völker, K.; Golf, S.W.; Wadepuhl, M.; Kraus, A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects: A double-blind, placebo-controlled, randomized trial. Diabetes Obes. Metab. 2011, 13, 281–284. [Google Scholar] [CrossRef] [PubMed]
  59. Oki, R.; Izumi, Y.; Fujita, K.; et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: A randomized clinical trial. JAMA Neurol. 2022, 79, 575–583. [Google Scholar] [CrossRef] [PubMed]
  60. EFSA Panel on Nutrition, Novel Foods and Food Allergens. Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA J. 2023, 21, 8006. [CrossRef] [PubMed]
  61. Morris, A.A.M.; et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J. Inherit. Metab. Dis. 2017, 40, 49–74. [Google Scholar] [CrossRef] [PubMed]
  62. Sinha, A.; Hollingsworth, K.; Ball, S.; Cheetham, T. Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J. Clin. Endocrinol. Metab. 2013, 98, E509–E513. [Google Scholar] [CrossRef] [PubMed]
  63. Burt, L.A.; et al. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: A randomized clinical trial. JAMA 2019, 322, 736–745. [Google Scholar] [CrossRef] [PubMed]
  64. National Institutes of Health; Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ (accessed on 10 November 2026).
  65. Demay, M.B.; et al. Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2024, 109, 1907–1947. [Google Scholar] [CrossRef] [PubMed]
  66. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001, 119, 1417–1436. [Google Scholar] [CrossRef] [PubMed]
  67. National Institutes of Health; Office of Dietary Supplements. Copper Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/ (accessed on 10 November 2026).
  68. O’Donohue, J.; Reid, M.; Varghese, A.; Portmann, B.; Williams, R. A case of adult chronic copper self-intoxication resulting in cirrhosis. Eur. J. Med. Res. 1999, 4, 252. Available online: https://pubmed.ncbi.nlm.nih.gov/10383882/. [PubMed]
  69. Marcocci, C.; Kahaly, G.J.; Krassas, G.E.; et al. Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med. 2011, 364, 1920–1931. [Google Scholar] [CrossRef] [PubMed]
  70. Lippman, S.M.; et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301, 39–51. [Google Scholar] [CrossRef] [PubMed]
  71. EFSA Panel on Nutrition, Novel Foods and Food Allergens. Scientific opinion on the tolerable upper intake level for selenium. EFSA J. 2023, 21, 7704. [CrossRef] [PubMed]
  72. Stoffel, N.U.; et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: Two open-label, randomised controlled trials. Lancet Haematol. 2017, 4, e524–e533. [Google Scholar] [CrossRef] [PubMed]
  73. National Institutes of Health; Office of Dietary Supplements. Iron Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/ (accessed on 10 November 2026).
  74. Mortensen, S.A.; Rosenfeldt, F.; Kumar, A.; et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC Heart Fail. 2014, 2, 641–649. [Google Scholar] [CrossRef] [PubMed]
  75. Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol. 2014, 71, 543–552. [CrossRef] [PubMed]
  76. National Institutes of Health; Office of Dietary Supplements. Dietary Supplements for Exercise and Athletic Performance Fact Sheet for Health Professionals. Available online: https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ (accessed on 10 November 2026).
  77. Kreider, R.B.; Kalman, D.S.; Antonio, J.; et al. International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation in exercise, sport, and medicine. J. Int. Soc. Sports Nutr. 2017, 14, 18. [Google Scholar] [CrossRef] [PubMed]
  78. Gordjinejad, A.; et al. Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Sci. Rep. 2024, 14, 4937. [Google Scholar] [CrossRef] [PubMed]
  79. Kumar, P.; et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J. Gerontol. A Biol. Sci. Med. Sci. 2023, 78, 75–89. Available online: https://pubmed.ncbi.nlm.nih.gov/35975308/. [CrossRef] [PubMed]
  80. Barcelos, I.; Shadiack, E.; Ganetzky, R.D.; Falk, M.J. Mitochondrial medicine therapies: Rationale, evidence, and dosing guidelines. Curr. Opin. Pediatr. 2020, 32, 707–718. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC7774245/. [CrossRef] [PubMed]
  81. Dollerup, O.L.; et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: Safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 2018, 108, 343–353. [Google Scholar] [CrossRef] [PubMed]
  82. Yoshino, M.; Yoshino, J.; Kayser, B.D.; et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021, 372, 1224–1229. [Google Scholar] [CrossRef] [PubMed]
  83. Moertel, C.G.; Fleming, T.R.; Creagan, E.T.; Rubin, J.; O’Connell, M.J.; Ames, M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: A randomized double-blind comparison. N. Engl. J. Med. 1985, 312, 137–141. [Google Scholar] [CrossRef] [PubMed]
  84. Bager, P.; Bossen, L.; Gantzel, R.; Grønbæk, H. High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial. PLoS ONE 2024, 19, e0301354. [Google Scholar] [CrossRef] [PubMed]
  85. Ziegler, D.; et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006, 29, 2365–2370. [Google Scholar] [CrossRef] [PubMed]
Table 1. Therapeutic exposures with reported mitochondrial effects and adverse findings by mechanism and clinical context.
Table 1. Therapeutic exposures with reported mitochondrial effects and adverse findings by mechanism and clinical context.
Therapeutic group Examples studied Reported mitochondrial effects Evidence and exposure context Representative references
1. Statins Atorvastatin; other statins examined in experimental work Reduced oxidative phosphorylation capacity and respiratory-chain inhibition Human + experimental. Eight adults receiving atorvastatin 80 mg/day for eight weeks showed >30% lower muscle oxidative phosphorylation capacity. No myalgia was reported and whole-body maximal aerobic capacity did not significantly change. Effects cannot be generalized across statins or doses. Ryan et al., 2024 [19]
2. Biguanide diabetes therapy Metformin Complex-I inhibition and reduced respiration Experimental mechanistic example. Concentration, tissue, and exposure duration are critical. Respiratory inhibition may contribute to therapeutic action and does not itself establish destructive mitochondrial toxicity. Owen et al., 2000 [20]
3. Proton-pump inhibitors Omeprazole Mitochondrial oxidative stress and ATP depletion in kidney cells Experimental. A possible mechanism of renal injury; does not establish widespread mitochondrial harm during ordinary clinical dosing. Distinct from medication-related magnesium/B12 depletion. Fontecha-Barriuso et al., 2020 [21]
4. Acetaminophen-containing analgesics Acetaminophen/paracetamol Mitochondrial damage contributing to hepatocyte death Human + experimental, principally overdose. Circulating markers of mitochondrial damage were measured in patients with overdose-related liver injury. This context should not be extrapolated to all therapeutic use. McGill et al., 2012 [22]
5. NSAIDs Diclofenac, indomethacin Uncoupling of oxidative phosphorylation and altered mitochondrial bioenergetics Experimental. Findings depend on agent, concentration, and tissue; the cited intact-cell study does not establish a uniform clinical NSAID-class effect. Krause et al., 2003 [23]
6. Systemic glucocorticoids Chronic systemic corticosteroid treatment Lower muscle complex-I activity and oxidative damage to mitochondrial and nuclear DNA Human observational evidence in treated patients, including muscle biopsies and exercise testing. Underlying illness and cumulative exposure must be considered; findings do not quantify risk from a brief course. Mitsui et al., 2002 [24]
7. Antibacterial antibiotics Linezolid, doxycycline, ciprofloxacin; aminoglycosides in genetically susceptible patients Inhibited mitochondrial translation; impaired mitochondrial DNA maintenance; reduced respiratory function Human evidence is particularly direct for prolonged linezolid exposure and aminoglycoside susceptibility genotypes. Doxycycline and ciprofloxacin findings are mainly experimental. Does not implicate all antibiotics. De Vriese et al., 2006 [25]; Prezant et al., 1993 [26]; Moullan et al., 2015 [27]; Hangas et al., 2018 [28]
8. Valproate therapy Valproic acid and related acid derivatives Inhibited alpha-lipoamide dehydrogenase and substrate oxidation Experimental in the cited 2017 study, including isolated rat mitochondria. Separately, clinical hepatotoxicity in POLG-related disorders underlies an official contraindication; this is not a class effect of all anticonvulsants. Kudin et al., 2017 [29]; official labeling [30]
9. Antidepressants Sertraline Uncoupling, complexes I/V inhibition, ATP depletion, and permeability transition in rat preparations; respiratory-chain deficiency in a selected clinical myopathy series Experimental in Li et al.; additional human tissue evidence in a 2024 sertraline-associated lipid-storage myopathy series. Neither establishes population incidence or a uniform antidepressant-class effect. Li et al., 2012 [31]; Hedberg-Oldfors et al., 2024 [32]
10. Antipsychotics Haloperidol, chlorpromazine, risperidone, quetiapine; clozapine and olanzapine in other models Respiratory-chain inhibition, reduced oxygen consumption/ATP, and altered mitochondrial regulation Predominantly experimental, with additional observational peripheral-blood findings. Patient-derived cell lines exposed in vitro remain experimental. Results differ substantially by drug and model. Modica-Napolitano et al., 2003 [33]; Scaini et al., 2018 [34]
11. Amiodarone antiarrhythmic therapy Amiodarone Lower membrane potential and ATP; impaired fatty-acid oxidation and complex-I/II-linked respiration Experimental, including primary adult human cardiomyocytes exposed for 24 hours at concentrations described by the investigators as near therapeutic. Does not directly measure toxicity incidence in treated patients. Krajčová et al., 2023 [35]
12. Intravenous anesthesia and sedation Propofol Mitochondrial structural injury; impaired bioenergetics implicated in infusion syndrome Human case/tissue evidence plus experimental literature. Prolonged, high-dose infusion is a key clinical context; brief procedural anesthesia is not equivalent to propofol infusion syndrome. Vollmer et al., 2018 [36]
13. Local anesthetics Bupivacaine, lidocaine, ropivacaine Mitochondrial DNA damage and ATP depletion; uncoupling, respiratory-chain inhibition, and oxidative stress in other experiments Experimental, including cultured human cartilage cells. Local concentration, exposure duration, and delivery site matter; findings do not imply equivalent risk from every injection. Grishko et al., 2010 [37]; Cela et al., 2010 [38]
14. Anthracycline chemotherapy Doxorubicin Mitochondrial iron accumulation, oxidative injury, and disturbed mitochondrial function Experimental + human cardiac-tissue findings. Higher mitochondrial iron in hearts with doxorubicin cardiomyopathy supports a mitochondrial contribution without establishing that it is the sole mechanism. Ichikawa et al., 2014 [39]; Zhang et al., 2012 [40]
Table 2. I-OM higher-dose ranges alongside published intervention evidence and documented adverse exposures.
Table 2. I-OM higher-dose ranges alongside published intervention evidence and documented adverse exposures.
Nutrient Mitochondrial relevance I-OM ranges and studied exposures with outcomes Documented adverse dose or toxicity context Higher-dose potential—evidence versus I-OM hypothesis
1. Thiamine—B1 Thiamine diphosphate supports pyruvate and α-ketoglutarate dehydrogenases, linking substrate oxidation to energy production. Author-recorded I-OM clinical range: 100–1,500+ mg/day; higher use requires indication-specific appraisal [5]. Published evidence: 600–1,800 mg/day for four weeks reduced fatigue versus placebo in 40 adults with quiescent IBD [46]. Oral pharmacokinetics studied to 1,500 mg per dose [47]. Historical Alzheimer studies tested 3–8 g/day, with inconsistent efficacy [48,49]. General oral toxic-dose threshold not established [6]. Small trials cannot establish long-term safety at several grams/day; oral and parenteral risks differ. I-OM opportunity: identify patients whose substrate oxidation responds to greater thiamine availability. Compare gram-level treatment with lower active doses, linking cofactor status to mitochondrial function and fatigue [46,47].
2. Riboflavin—B2 Supplies FMN/FAD for electron transfer and fatty-acid oxidation. Author-recorded I-OM clinical range: 200–800+ mg/day; higher use requires indication-specific appraisal [5]. 400 mg/day is a commonly studied migraine dose, not a stated ceiling. Published evidence: 400 mg/day for three months reduced migraine frequency in a 55-participant randomized trial [50]. Riboflavin-responsive MADD provides a disease-specific precedent [43]. These are clinical responses, not proof of enhancement in replete adults. No general human toxic-dose threshold established [7]; long-term safety at the proposed higher exposure is not defined by this evidence. I-OM opportunity: test whether greater FMN/FAD availability improves electron transfer or fatty-acid oxidation in responsive metabolic phenotypes. Vitamin-responsive disease supplies a precedent for cofactor-directed treatment [43,44].
3. Niacin—B3 Supplies NAD/NADP precursors for redox reactions and energy metabolism. Author-recorded I-OM clinical range: 500–3,000 mg/day [5]. Unverified historical upper-exposure claims are catalogued separately in Appendix A; they are not efficacy or safety evidence. Published evidence: 750–1,000 mg/day nicotinic acid increased NAD availability and improved muscle-related outcomes in a small mitochondrial-myopathy study [51]. 1,500–2,000 mg/day extended-release niacin improved lipids but did not add cardiovascular benefit to statin therapy in AIM-HIGH [52]. Doses above 500 mg/day have been associated with usually mild, transient aminotransferase elevations; these are more frequent above 3,000 mg/day. Serious liver injury occurs particularly with sustained-release formulations, sometimes at lower doses [53]. I-OM opportunity: restore NAD availability in responsive mitochondrial or metabolic phenotypes. Compare nutrient forms, tissue responses, and functional outcomes; nicotinic acid, nicotinamide, NR, and NMN have distinct pharmacology.
4. Vitamin C Redox and cofactor functions; experimental protection of mitochondrial DNA and membrane potential [54]. Author-proposed oral range: 10–15 g/day in divided doses for selected contexts [5]. The broader recorded exposure claims are preserved in Appendix A. These are practice proposals, not trial-established mitochondrial doses. Single 10 g IV reduced current fatigue in a short trial [55]. Oral/IV exposures differ substantially [56]; Section 6.4 separates practice, outcomes, and pharmacokinetics. No general human toxic-dose threshold established. Long-term safety of the proposed high oral range is unresolved. Increased urinary oxalate and urate were observed at 1,000 mg/day in a healthy-volunteer depletion–repletion study; these biochemical changes do not establish clinical toxicity [57]. I-OM research priority: compare 10–15 g/day oral treatment with lower active doses in defined metabolic contexts. Test mitochondrial function and patient-important outcomes. Oral and IV regimens require separate evidence.
5. Magnesium Supports Mg–ATP-dependent reactions, substrate metabolism, and ion regulation. Author-recorded I-OM increased-demand range: 1,000–2,000+ mg/day elemental; higher oral or IV use requires separate appraisal [5]. Published evidence: 365 mg/day supplemental elemental magnesium for six months improved fasting glucose and some insulin-sensitivity indices in a small trial of normomagnesemic, overweight, insulin-resistant adults [58]. These were metabolic outcomes, not direct mitochondrial measurements. Toxicity reported with laxative/antacid exposures typically providing >5,000 mg/day. Lower exposures can be toxic with impaired renal clearance; this is not a minimum toxic dose [9]. I-OM opportunity: improve Mg–ATP-dependent function where availability is limiting, including patients with normal serum values but plausible metabolic constraints [58]. Renal clearance and functional response guide assessment [9].
6. Vitamin B12 Required for mitochondrial methylmalonyl-CoA mutase. Author-recorded I-OM oral range: 1–5 mg/day; further use requires indication-specific appraisal [5]. Published evidence: Oral 647–1,032 µg/day modeled to achieve 80–90% of maximal MMA reduction in mild deficiency [45]. 50 mg IM twice weekly for 16 weeks slowed functional decline in a selected early-ALS trial [59]. Routes and indications differ. No general human toxic-dose threshold established [8]; this does not define long-term safety at every dose or route. I-OM opportunity: investigate pharmacological B12 beyond routine replacement in defined neurological or metabolic phenotypes. The selected early-ALS trial provides a clinical precedent [59]; direct mitochondrial mechanisms remain to be tested.
7. Vitamin B6 Supports amino-acid metabolism, heme synthesis, and transsulfuration pathways. Author-recorded I-OM range: 50–100 mg/day; higher therapeutic use requires indication-specific appraisal [5]. This overlaps reported neuropathy exposures [60]. Published evidence: For a supervised pyridoxine-response assessment in CBS deficiency, guidance uses 10 mg/kg/day, maximum 500 mg/day, for six weeks with homocysteine monitoring [61]. This is a specialist metabolic protocol, not general mitochondrial dosing. Neuropathy has been reported with prolonged intakes around 50 mg/day; lower-dose reports also exist, with variable exposure verification and causal certainty. Minimum toxic dose not established [60]. I-OM opportunity: use responsive-enzyme phenotypes to investigate cofactor-directed treatment [61]. Functional markers and clinical response should guide the question; dose and duration must account for neuropathy risk [60].
8. Vitamin D Regulates muscle and calcium physiology; mitochondrial effects remain under investigation. Author-proposed I-OM serum 25(OH)D: 50–100 ng/mL; selected supervised contexts 100–150 ng/mL [5]. These are proposed concentration targets, not established safety windows. Published evidence: After treating severe deficiency, mean serum 25(OH)D rose to 113.8 nmol/L (45.5 ng/mL) with improved muscle oxidative function in a small before–after study [62]. 4,000 and 10,000 IU/day studied for three years did not improve bone outcomes [63]. Universal toxic dose not established. A three-year trial found greater radial volumetric bone-density loss at 4,000 and 10,000 IU/day versus 400 IU/day—an adverse outcome, not a poisoning threshold [63]. Exposure–response hypothesis: test added functional benefit beyond correction. 100–150 ng/mL is an unproven research range, not an established safety or efficacy window; no universal optimal serum target is established [64,65].
9. Zinc Supports enzyme activity, protein maintenance, and cellular redox regulation. Author-recorded I-OM clinical range: 40–75+ mg/day elemental; higher use requires indication-specific appraisal [5]. Published evidence: AREDS tested 80 mg/day zinc with 2 mg/day copper, alone or with antioxidant vitamins; the combined regimen reduced progression to advanced AMD in higher-risk participants [66]. This is disease-specific evidence, not a mitochondrial enhancement dose. ≥50 mg/day for weeks can inhibit copper absorption, potentially causing secondary deficiency and neurological or hematological injury [13]. I-OM opportunity: investigate higher-dose support for cellular maintenance and redox regulation in responsive contexts. AREDS supplies a disease-specific precedent [66]; coordinated copper availability is essential to interpretation.
10. Copper Required for cytochrome-c oxidase—complex IV—and normal iron handling. Author-recorded I-OM clinical range: 3–5 mg/day; higher use requires indication-specific appraisal [5]. Published evidence: 2 mg/day copper accompanied high-dose zinc in AREDS to reduce copper-depletion risk [66]. This cointervention does not establish independent copper efficacy. Treat confirmed deficiency with an individualized regimen [67]. 30–60 mg/day for three years caused severe cirrhosis requiring transplantation in a case report. Minimum toxic dose not established [68]. I-OM opportunity: test restoration of complex-IV-related function when copper availability is constrained. The research target is effective enzyme support and nutritional balance, with excess exposure avoided [67,68].
11. Selenium Supports glutathione peroxidases and thioredoxin reductases involved in redox defense. Author-recorded I-OM clinical range: 300–400 µg/day; higher use requires indication-specific appraisal [5]. Published evidence: 100 µg twice daily (as sodium selenite) for six months improved eye-related outcomes in mild Graves orbitopathy [69]. A 200 µg/day supplement in SELECT had a different benefit–risk profile [70]. Form, baseline status, and disease matter. A 200 µg/day supplement increased alopecia in SELECT; EFSA estimated approximately 330 µg/day total intake in that setting [70,71]. I-OM opportunity: investigate whether improving selenium-dependent redox capacity benefits selected low-status or high-demand groups. Compare functional responses and harms across formulations and baseline status [69,71].
12. Iron Required for iron–sulfur clusters, cytochromes, and oxygen delivery. Oral 60 mg per dose on consecutive or alternate days, and 120 mg once versus 60 mg twice daily, studied in iron-depleted women. Timing altered absorption [72]. These are deficiency-treatment and absorption studies. Acute ingestion >20 mg/kg can cause serious gastrointestinal injury; approximately 60 mg/kg or more can cause severe systemic poisoning. These are single-ingestion exposures [73]. I-OM opportunity: improve oxygen delivery and iron-dependent energy pathways when deficient. Optimize dose, schedule, and absorption using hematological response and iron indices; excess storage is not the intended endpoint [72,73].
13. Coenzyme Q10 Electron carrier between complexes I/II and III; membrane redox functions. Author-recorded I-OM clinical range: 300–1,200+ mg/day; higher use requires indication-specific appraisal [5]. Published evidence: 300 mg/day improved heart-failure outcomes in Q-SYMBIO [74]. In early Parkinson disease, 1,200 or 2,400 mg/day showed no clinical benefit in a 600-participant trial [75]. Higher exposure did not guarantee efficacy. General human toxic-dose threshold not established; this does not establish absence of adverse effects or interactions. I-OM opportunity: improve electron-transfer support in responsive disease and investigate formulation-dependent tissue delivery. Positive heart-failure and negative Parkinson trials make phenotype and exposure central to dose optimization [74,75].
14. Creatine Supports phosphocreatine-mediated ATP buffering and energy transfer. Author-recorded I-OM clinical range: 10–20 g/day; higher use requires indication-specific appraisal [5]. Published evidence: Maintenance 3–5 g/day; loading approximately 20 g/day for 5–7 days in exercise practice [76,77]. A single 0.35 g/kg dose improved cognition and changed cerebral high-energy phosphates during sleep deprivation in a small crossover study [78]. General human toxic-dose threshold not established; gastrointestinal intolerance and interpretation of renal markers require attention. I-OM opportunity: extend ATP-buffering support to periods of increased brain or muscle energy demand. Acute high-dose findings support further context-specific dose trials, with chronic regimens evaluated separately [77,78].
15. Glycine + N-acetylcysteine—GlyNAC Supplies precursors for glutathione synthesis and redox support. 100 mg/kg/day each of glycine and NAC for 16 weeks in a 24-person older-adult RCT improved mitochondrial-related measures and physical function [79]. At 70 kg, this equals 7 g/day of each (calculated illustration). General toxic-dose threshold for the combination not established; a small 16-week trial cannot define long-term safety. I-OM opportunity: restore glutathione-related metabolic resilience in responsive older adults [79]. Compare lower and higher doses, tissue and functional responses, and sustained benefit through independent replication.
Table notes. Bold author-recorded I-OM ranges are summarized from the monographs [5] and are distinct from the published evidence that follows. The word clinical describes the author’s proposed context of use, not proof of efficacy or safety. The appendix preserves the selected dose entries and their source limitations. They are not established maximum safe doses. Higher individualized dosing is an open research or clinical-appraisal category, not evidence of unlimited safety. In the adverse-exposure column, “not established” refers to the absence of a reliable general human toxic-dose threshold; it does not establish absence of adverse effects. Elsewhere, the phrase refers to the specific efficacy or dose question stated in that cell. Documented adverse exposures are specific to formulation, route, duration, and susceptibility. Biochemical changes, clinical adverse outcomes, and overt poisoning are distinguished. Higher-dose hypotheses should be tested against functional and patient-important outcomes, rather than changes in nutrient concentrations alone. Doses shown include author-proposed ranges and selected research or disease-specific exposures, not maximum safe doses or a combined prescription. “Higher” is relative to ordinary nutritional provision or common maintenance use; it is not a uniform pharmacological category. Measured concentrations, modeled predictions, and proposed research ranges are explicitly distinguished. The absence of a validated high blood target is an evidence gap, not proof that optimization is impossible.
Table 3. Clinical interpretation of the evidence used in this review.
Table 3. Clinical interpretation of the evidence used in this review.
Evidence situation Supported interpretation Implication for healthy longevity
Deficiency or impaired nutrient handling Treat the identified condition with an appropriate regimen and reassess response Preserve function by correcting a credible constraint; benefit in deficient patients does not establish enhancement in replete adults
Defined disease or susceptible genotype Use indication-specific evidence and specialist guidance Riboflavin-responsive disease, primary CoQ disorders, and medication susceptibility require individual interpretation
Experimental mitochondrial drug effect Identify a plausible mechanism and relevant exposure conditions Investigate clinical risk; do not equate a laboratory effect with net harm from necessary therapy
Small human supplement trial or surrogate endpoint Consider preliminary benefit within the population and outcome studied Justifies replication and dose-ranging research; does not establish lifespan extension
Proposed I-OM integration Examine injury burden, nutrient constraints, and physiological demand together A clinical reasoning and research framework whose combined effectiveness remains to be tested
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.